NYSE:BHVN - Biohaven Pharmaceutical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $33.84 -1.02 (-2.93 %) (As of 08/21/2018 01:44 AM ET)Previous Close$34.86Today's Range$33.42 - $35.4252-Week Range$16.50 - $44.28Volume185,900 shsAverage Volume544,867 shsMarket Capitalization$1.31 billionP/E Ratio-6.77Dividend YieldN/ABeta1.35 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc. Receive BHVN News and Ratings via Email Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNYSE:BHVN CUSIPN/A Webwww.biohavenpharma.com Phone203-404-0410 Debt Debt-to-Equity RatioN/A Current Ratio6.80 Quick Ratio6.80 Price-To-Earnings Trailing P/E Ratio-6.77 Forward P/E Ratio-5.04 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$3.66 per share Price / Book9.25 Profitability EPS (Most Recent Fiscal Year)($5.00) Net Income$-127,190,000.00 Net MarginsN/A Return on Equity-137.13% Return on Assets-120.17% Miscellaneous Employees42 Outstanding Shares40,130,000Market Cap$1.31 billion Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions What is Biohaven Pharmaceutical's stock symbol? Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN." How were Biohaven Pharmaceutical's earnings last quarter? Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) issued its earnings results on Tuesday, May, 15th. The company reported ($2.32) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by $1.21. View Biohaven Pharmaceutical's Earnings History. When is Biohaven Pharmaceutical's next earnings date? Biohaven Pharmaceutical is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for Biohaven Pharmaceutical. What price target have analysts set for BHVN? 7 brokers have issued 1-year price objectives for Biohaven Pharmaceutical's stock. Their forecasts range from $40.00 to $50.00. On average, they expect Biohaven Pharmaceutical's stock price to reach $45.50 in the next twelve months. This suggests a possible upside of 34.5% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical. What is the consensus analysts' recommendation for Biohaven Pharmaceutical? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical. What are Wall Street analysts saying about Biohaven Pharmaceutical stock? Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock: 1. Canaccord Genuity analysts commented, "We are updating our BHVN model after the company recently reported its 2Q18 results and filed its 10-Q. We are not making any substantial changes to our model and are maintaining our DCF-based price target at $43, which represents ~20% upside potential from current levels. As we noted recently (see here), we believe the pullback from recent highs affords an opportunity to buy the stock ahead of upcoming data-related events in 4Q18." (8/17/2018) 2. Needham & Company LLC analysts commented, "Biohaven reported 2Q18 financial results this wk and we spoke w/ mgmt for update. Biohaven announced encouraging results from BHV-0223 Phase 2 trial in Anxiety and plans to bring related drug troriluzole forward in a registration trial in both this indication and Spinocerebellar Ataxia by YE18. Enrollment has been completed in Phase 3 trial of ODT formulation of lead asset rimegepant in Acute Migraine and results expected 4Q18. Rimegepant open label Phase 3 safety trial has reached 1600 pts and mgmt reiterated guidance for interim analysis 4Q18. NDA submission in Acute Migraine probably mid-2019. Phase 3 rimegepant trial initiation in Chronic Migraine on track 4Q18. We continue to believe rimegepant will be an attractive option for both Acute and Chronic Migraine. Rest of pipeline higher risk, but still underappreciated." (8/17/2018) 3. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (8/14/2018) 4. Cantor Fitzgerald analysts commented, ": Following our meeting with CEO Vlad Coric and CFO Jim Engelhart earlier this week, we reaffirm our Overweight rating on BHVN stock, and are increasing our 12-month price target to $50, from $42, driven by multiple expansion. We think the Street’s focus on rimegepant acute oral CGRP data has led to an under-appreciation of Biohaven’s other opportunities to drive long term share holder value beyond current levels. The takeaways from our meeting are detailed below and underscore our belief BHVN shares remain undervalued at current levels." (7/12/2018) Who are some of Biohaven Pharmaceutical's key competitors? Some companies that are related to Biohaven Pharmaceutical include Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY) and Opko Health (OPK). Who are Biohaven Pharmaceutical's key executives? Biohaven Pharmaceutical's management team includes the folowing people: Dr. Vladimir Coric, CEO & Director (Age 47)Mr. James Engelhart, Chief Financial Officer (Age 54)Dr. Charles Conway, Chief Scientific Officer (Age 56)Dr. Robert Berman, Chief Medical Officer (Age 55)Mr. John Tilton, Chief Commercial Officer (Age 50) When did Biohaven Pharmaceutical IPO? (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Has Biohaven Pharmaceutical been receiving favorable news coverage? Press coverage about BHVN stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biohaven Pharmaceutical earned a news impact score of 0.15 on Accern's scale. They also gave media headlines about the company an impact score of 46.88 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Biohaven Pharmaceutical. Who are Biohaven Pharmaceutical's major shareholders? Biohaven Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (8.49%), BlackRock Inc. (5.38%), VHCP Management II LLC (3.64%), FMR LLC (3.48%), Eagle Asset Management Inc. (2.62%) and Emerald Advisers Inc. PA (1.04%). Company insiders that own Biohaven Pharmaceutical stock include Albert Cha, Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical. Which major investors are selling Biohaven Pharmaceutical stock? BHVN stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Eagle Asset Management Inc., Sigma Planning Corp and Rhumbline Advisers. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical. Which major investors are buying Biohaven Pharmaceutical stock? BHVN stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Schwab Charles Investment Management Inc., Emerald Advisers Inc. PA, Bank of America Corp DE, VHCP Management II LLC, DAFNA Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Albert Cha, James Engelhart and Robert Berman. View Insider Buying and Selling for Biohaven Pharmaceutical. How do I buy shares of Biohaven Pharmaceutical? Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Biohaven Pharmaceutical's stock price today? One share of BHVN stock can currently be purchased for approximately $33.84. How big of a company is Biohaven Pharmaceutical? Biohaven Pharmaceutical has a market capitalization of $1.31 billion. The company earns $-127,190,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Biohaven Pharmaceutical employs 42 workers across the globe. How can I contact Biohaven Pharmaceutical? Biohaven Pharmaceutical's mailing address is 234 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410. MarketBeat Community Rating for Biohaven Pharmaceutical (NYSE BHVN)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 150 (Vote Outperform)Underperform Votes: 199 (Vote Underperform)Total Votes: 349MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/21/2018 by MarketBeat.com StaffFeatured Article: What do investors mean by earnings per share?